This particular prime-boost immunization approach (MVA is used as a prime booster) induces higher CD8+ T cell responses than single vector immunization, and it confers 21% sterile short-term protection as determined by CHMI in malaria-naive adults [28,34]. This evidence concerns the gene CD8A and malaria.